TREATMENT OF SUBCLINICAL HYPERTHYROIDISM SIGNIFICANTLY REDUCES THE RATE AND SYMPTOMS OF ASSOCIATED CARDIOVASCULAR ABNORMALITIES
DOI:
https://doi.org/10.5457/ams.v38i1.36Keywords:
subclinical hyperthyroidism, treatment, cardiovascular, echosonography, metimazolAbstract
Background: The treatment of subclinical hyperthyroidism (SH) is still controversial since there are no huge clinical trials that tried to assess the effects of therapy of SH.
Aim: We aimed to determine whether a frequency and symptoms of cardiovascular abnormalities commonly associated with hyperthyroidism will reduce after the treatment with methimazole in a cohort of patients with established and untreated SH.
Methods: We prospectively evaluated 29 patients with recently diagnosed SH that were naïve to any treatment directed against over production of thyroid hormones. We evaluated each patient by assesing the rate of specific symptoms, clinical examination, electrocardiography, heart ultrasonography and determination of thyroid hormones and antibodies.
Results: The mean age in our sample was 49±13 years with 21 (79.32%) women. The average duration of methimazole treatment was 7±1 months. Mean values of all thyroid hormones and thyroid antibodies significantly declined after the treatment (p<0.05). A significant decrease in frequency of palpitation, irregular heart beat and dyspnoea was observed in patients after the treatment (p<0.001). There was no difference in mean values of diastolic pressure before and after the treatment, however systolic pressure and heart rate declined significantly after the treatment (p<0.0001). A clear reduction in LV mass, interventricular septum thickness and thickness of posterior wall of LV was demonstrated as a response to treatment of subclinical hyperthyroidism (p<0.001). Supraventricular premature beats and sinus tachycardia completely disappeared after the treatment (p<0.002). Although there was a clear tendency for a reduction in frequencies of paroxysmal supraventricular tachycardia, atrial fibrilation and right bundle branch block, it was not statistically significant.
Conclusion: Cardiovascular abnormalities associated with SH are significantly reduced after treatment with methimazole and achieving euthyroidism. Our results indicate that treatment of this syndrome is justified as it may reverse potentially harmful effects on cardiovascular system.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
